The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle cell disease (SCD).
Telix Pharmaceuticals has completed Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for TLX250-CDx (Zircaix), a radiodiagnostic agent for identifying clear cell renal cell carcinoma (ccRCC) in kidney cancer patients.
Weave Bio has secured $10m in a seed funding round spearheaded by Innovation Endeavors and Magnetic Ventures.
UK-based biotechnology company ExpressionEdits has secured $13m in a seed funding round to advance the development of protein based therapies leveraging artificial intelligence (AI)-driven intronization technology.
Lucy Therapeutics (LucyTx) has secured $12.5m in additional financing round to advance the development of new treatments for Alzheimer's and Parkinson's diseases.
Venture-backed biotechnology company RevolKa has entered into a master service agreement with Daiichi Sankyo for functional proteins.
Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.
Teva and Alvotech have announced the US launch of SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to the reference product Humira to treat arthritis.
ERS Genomics and IRBM have entered into a non-exclusive license agreement, granting the latter access to ERS Genomics' extensive clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio.
FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.